Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling

Journal of Immunology

Volumn 185, Issue 11, 2010, Pages 6555-6562

  Peters, Anna L ^a   Bishop, Gail A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Microbiology ^*  (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; IMMUNOGLOBULIN M; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN C JUN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BINDING SITE; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD40; BINDING SITES; CELL LINE; CLONE CELLS; GENETIC VARIATION; HUMANS; INTERLEUKIN-6; MICE; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3; TNF RECEPTOR-ASSOCIATED FACTOR 6; UP-REGULATION;

EID: 78650642312     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000135     Document Type: Article

References (42)

1. Bishop, G. A., C. R. Moore, P. Xie, L. L. Stunz, and Z. J. Kraus. 2007. TRAF proteins in CD40 signaling. Adv. Exp. Med. Biol. 597:131-151.
2. Schönbeck, U., and P. Libby. 2001. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58:4-43.
3. Peters, A. L., L. L. Stunz, and G. A. Bishop. 2009. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 21:293-300.
4. Law, C.-L., and I. S. Grewal. 2009. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. In Therapeutic Targets of the TNF Superfamily. I. S. Grewal, ed. Landes Bioscience, Austin, TX, p. 8-36.
5. Tomer, Y., E. Concepcion, and D. A. Greenberg. 2002. A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid 12:1129-1135.
6. Kim, T. Y., Y. J. Park, J. K. Hwang, J. Y. Song, K. S. Park, B. Y. Cho, and D. J. Park. 2003. A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid 13:919-925.
7. Raychaudhuri, S., E. F. Remmers, A. T. Lee, R. Hackett, C. Guiducci, N. P. Burtt, L. Gianniny, B. D. Korman, L. Padyukov, F. A. Kurreeman, et al. 2008. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat. Genet. 40:1216-1223.
8. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). 2009. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41:824-828.
9. Hostager, B. S., and G. A. Bishop. 1999. Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J. Immunol. 162:6307-6311.
10. Xie, P., B. S. Hostager, and G. A. Bishop. 2004. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J. Exp. Med. 199:661-671.
11. Rowland, S. L., M. M. Tremblay, J. M. Ellison, L. L. Stunz, G. A. Bishop, and B. S. Hostager. 2007. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J. Immunol. 179:4645-4653.
12. Stunz, L. L., L. K. Busch, M. E. Munroe, C. D. Sigmund, L. T. Tygrett, T. J. Waldschmidt, and G. A. Bishop. 2004. Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 21:255-266.
13. Wu, S., P. Xie, K. Welsh, C. Li, C. Ni, X. Zhu, J. C. Reed, A. C. Satterthwait, G. A. Bishop, and K. R. Ely. 2005. LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3. J. Biol. Chem. 280:33620-33626.
14. Peters, A. L., R. M. Plenge, R. R. Graham, D. M. Altshuler, K. L. Moser, P. M. Gaffney, and G. A. Bishop. 2008. A novel polymorphism of the human CD40 receptor with enhanced function. Blood 112:1863-1871.
15. Fernandez, M. 2007. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 57:576-584.
16. Hostager, B. S., S. A. Haxhinasto, S. L. Rowland, and G. A. Bishop. 2003. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J. Biol. Chem. 278:45382-45390.
17. Kim, K. J., C. Kanellopoulos-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:549-554.
18. + B cells by clonal T cells and antigen. Proc. Natl. Acad. Sci. USA 83:7410-7414.
19. Baccam, M., and G. A. Bishop. 1999. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur. J. Immunol. 29:3855-3866.
20. Hostager, B. S., and G. A. Bishop. 2002. Role of TNF receptor-associated factor 2 in the activation of IgM secretion by CD40 and CD120b. J. Immunol. 168:3318-3322.
21. Hostager, B. S., I. M. Catlett, and G. A. Bishop. 2000. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J. Biol. Chem. 275:15392-15398.
22. + murine B cell lymphomas specific for erythrocyte membranes. J. Exp. Med. 163:155-165.
23. Lu, L., W. J. Cook, L. Lin, and R. J. Noelle. 2003. CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J. Biol. Chem. 278:45414-45418.
24. Pullen, S. S., H. G. Miller, D. S. Everdeen, T. T. A. Dang, J. J. Crute, and M. R. Kehry. 1998. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 37:11836-11845.
25. Graham, J. P., C. R. Moore, and G. A. Bishop. 2009. Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1. J. Immunol. 183:2966-2973.
26. Rothe, M., S. C. Wong, W. J. Henzel, and D. V. Goeddel. 1994. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78:681-692.
27. Leo, E., K. Welsh, S. Matsuzawa, J. M. Zapata, S. Kitada, R. S. Mitchell, K. R. Ely, and J. C. Reed. 1999. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-κB and Jun. N-terminal kinase activation. J. Biol. Chem. 274:22414-22422.
28. Baccam, M., S. Y. Woo, C. Vinson, and G. A. Bishop. 2003. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-κB, AP-1, and C/EBP. J. Immunol. 170:3099-3108.
29. Jalukar, S. V., B. S. Hostager, and G. A. Bishop. 2000. Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J. Immunol. 164:623-630.
30. Rooney, I. A., K. D. Butrovich, A. A. Glass, S. Borboroglu, C. A. Benedict, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, and C. F. Ware. 2000. The lymphotoxin-b receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275:14307-14315.
31. Häcker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L.-C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Häcker, et al. 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439:204-207.
32. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar, A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptordependent and-independent antiviral response. Nature 439:208-211.
33. Van Arsdale, T. L., S. L. Van Arsdale, W. R. Force, B. N. Walter, G. Mosialos, E. Kieff, J. C. Reed, and C. F. Ware. 1997. Lymphotoxin-β receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor κB. Proc. Natl. Acad. Sci. USA 94:2460-2465.
34. Li, X. 2008. Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine 41:105-113.
35. Dadgostar, H., S. E. Doyle, A. Shahangian, D. E. Garcia, and G. Cheng. 2003. T3JAM, a novel protein that specifically interacts with TRAF3 and promotes the activation of JNK. FEBS Lett. 553:403-407.
36. Qian, Y., J. Qin, G. Cui, M. Naramura, E. C. Snow, C. F. Ware, R. L. Fairchild, S. A. Omori, R. C. Rickert, M. L. Scott, et al. 2004. Act1, a negative regulator in CD40-and BAFF-mediated B cell survival. Immunity 21:575-587.
37. Kanamori, M., C. Kai, Y. Hayashizaki, and H. Suzuki. 2002. NF-κB activator Act1 associates with IL-1/Toll pathway adaptor molecule TRAF6. FEBS Lett. 532:241-246.
38. Claudio, E., S. U. Sønder, S. Saret, G. Carvalho, T. R. Ramalingam, T. A. Wynn, A. Chariot, A. Garcia-Perganeda, A. Leonardi, A. Paun, et al. 2009. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J. Immunol. 182:1617-1630.
39. Ni, C. Z., K. Welsh, E. Leo, C. K. Chiou, H. Wu, J. C. Reed, and K. R. Ely. 2000. Molecular basis for CD40 signaling mediated by TRAF3. Proc. Natl. Acad. Sci. USA 97:10395-10399.
40. McWhirter, S. M., S. S. Pullen, J. M. Holton, J. J. Crute, M. R. Kehry, and T. Alber. 1999. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc. Natl. Acad. Sci. USA 96:8408-8413.
41. Ye, H., J. R. Arron, B. Lamothe, M. Cirilli, T. Kobayashi, N. K. Shevde, D. Segal, O. K. Dzivenu, M. Vologodskaia, M. Yim, et al. 2002. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418:443-447.
42. Kraus, Z. J., H. Nakano, and G. A. Bishop. 2009. TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40. Proc. Natl. Acad. Sci. USA 106:17140-17145.